【摘要】 目的:探讨吡柔比星巩固治疗急性早幼粒细胞白血病(APL)疗效及不良反应方法:回顾性分析2006年1月至2011年8月北京大学深圳医院血液科收治的初治APL患者72例,完全缓解58例,分为TA组(吡柔比星+阿糖胞苷)26例和DA组(柔红霉素+阿糖胞苷)32例,比较两组疗效及不良反应。结果:58例患者中复发5例,其中TA组1例,DA组4例,虽然无统计学差异,但TA组比DA组2年复发率更低(5.0%vs.13.0%),3年无病生存率更高(93.3%vs.76.5%)。两组血液学毒性的发生率及严重程度相似。但心脏毒性方面,TA组仅9.2%(11例)出现轻微短暂心电图T波改变,无1例出现ST-T改变、心律失常或心肌酶升高。心脏不良事件发生率低于DA组。结论:TA与DA方案巩固治疗APL疗效相似,不良反应两组间无显著差异,吡柔比星心脏毒性更低。TA方案可作为急性早幼粒细胞白血病巩固治疗化疗方案之一。更多还原

【Abstract】 Objective:To explore the effectiveness and side effects of pirarubicin in the consolidation chemotherapy of acute promyelocytic leukemia(APL ).Methods:We retrospectively studied 58 cases of newly diagnosed APL that achieved complete remission( CR ).The patients were divided into two groups,with 26 cases in the TA group(pirarubicin + cytarabin ),and 32 cases in the DA group( daunorubicin + cytarabin ).Results:Of the 58 patients,5 relapsed:1 case in the TA group and 4 cases in DA group.Although no significant difference was observed between the two groups,the 2-year cumulative incidence of relapse was lower in the TA group than the DA group (5.0%vs.13.0%).The 3-year event free survival(EFS ) was higher in the TA group(93.3%vs.76.5%).The incidence and the degree of hematologic toxicity were similar.A mild transient T-wave abnormality was observed in 9.2%of the chemotherapy cycles in the TA group. The TA group had a lower incidence of cardiac toxicity than the DA group.Conclusion:The TA and DA regimens have similar effects on the consolidation chemotherapy of APL.The difference in side effects between the two groups was not significant.Pirarubicin has a lower incidence of cardiac toxicity.The TA regimen(pirarubicin + cytarabin ) may be an alternative to APL consolidation therapy.更多还原